Advertisement

Inactivation of Non-canonical Cyclic Nucleotides: Hydrolysis and Transport

Chapter
First Online:
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 238)

Abstract

This chapter addresses cNMP hydrolysis by phosphodiesterases (PDEs) and export by multidrug resistance associated proteins (MRPs). Both mechanisms are well-established for the canonical cNMPs, cAMP, and cGMP. Increasing evidence shows that non-canonical cNMPs (specifically cCMP, cUMP) are also PDE and MRP substrates. Hydrolysis of cUMP is achieved by PDE 3A, 3B, and 9A, which possibly explains the cUMP-degrading activities previously reported for heart, adipose tissue, and brain. Regarding cCMP, the only known “conventional” (class I) PDE that hydrolyzes cCMP is PDE7A. Older reports describe cCMP-degrading PDE-like activities in mammalian tissues, bacteria, and plants, but the molecular identity of these enzymes is not clear. High K M and V max values, insensitivity to common inhibitors, and unusually broad substrate specificities indicate that these activities probably do not represent class I PDEs. Moreover, the older results have to be interpreted with caution, since the historical analytical methods were not as reliable as modern highly sensitive and specific techniques like HPLC-MS/MS. Besides PDEs, the transporters MRP4 and 5 are of major importance for cAMP and cGMP disposal. Additionally, both MRPs also export cUMP, while cCMP is only exported by MRP5. Much less data are available for the non-canonical cNMPs, cIMP, cXMP, and cTMP. None of these cNMPs has been examined as MRP substrate. It was shown, however, that they are hydrolyzed by several conventional class I PDEs. Finally, this chapter reveals that there are still large gaps in our knowledge about PDE and MRP activities for canonical and non-canonical cNMPs. Future research should perform a comprehensive characterization of the known PDEs and MRPs with the physiologically most important cNMP substrates.

Keywords

cCMP cUMP Multifunctional PDE Non-canonical cyclic nucleotides Phosphodiesterases 
This is a preview of subscription content, log in to check access.

References

  1. Albrecht P, Henke N, Tien ML, Issberner A, Bouchachia I, Maher P, Lewerenz J, Methner A (2013) Extracellular cyclic GMP and its derivatives GMP and guanosine protect from oxidative glutamate toxicity. Neurochem Int 62:610–619PubMedCrossRefGoogle Scholar
  2. Al-Shboul O, Mahavadi S, Sriwai W, Grider JR, Murthy KS (2013) Differential expression of multidrug resistance protein 5 and phosphodiesterase 5 and regulation of cGMP levels in phasic and tonic smooth muscle. Am J Physiol Gastrointest Liver Physiol 305:G314–G324PubMedPubMedCentralCrossRefGoogle Scholar
  3. Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F, Manganiello V, Stratakis CA (2014) Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 35:195–233PubMedCrossRefGoogle Scholar
  4. Bähre H, Hartwig C, Munder A, Wolter S, Stelzer T, Schirmer B, Beckert U, Frank DW, Tümmler B, Kaever V, Seifert R (2015) cCMP and cUMP occur in vivo. Biochem Biophys Res Commun 460:909–914PubMedPubMedCentralCrossRefGoogle Scholar
  5. Beavo JA, Hardman JG, Sutherland EW (1971) Stimulation of adenosine 3′,5′-monophosphate hydrolysis by guanosine 3′,5′-monophosphate. J Biol Chem 246:3841–3846PubMedGoogle Scholar
  6. Beckert U, Wolter S, Hartwig C, Bähre H, Kaever V, Ladant D, Frank DW, Seifert R (2014) ExoY from Pseudomonas aeruginosa is a nucleotidyl cyclase with preference for cGMP and cUMP formation. Biochem Biophys Res Commun 450:870–874PubMedPubMedCentralCrossRefGoogle Scholar
  7. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520PubMedCrossRefGoogle Scholar
  8. Bergstrand H, Lundquist B, Schurmann A (1978) Cyclic nucleotide phosphodiesterase. Partial purification and characterization of a high affinity enzyme activity from human lung tissue. J Biol Chem 253:1881–1891PubMedGoogle Scholar
  9. Berrisch S, Ostermeyer J, Kaever V, Kälble S, Hilfiker-Kleiner D, Seifert R, Schneider EH (2016) cUMP hydrolysis by PDE3A. Naunyn Schmiedebergs Arch Pharmacol (in press)Google Scholar
  10. Beste KY, Seifert R (2013) cCMP, cUMP, cTMP, cIMP and cXMP as possible second messengers: development of a hypothesis based on studies with soluble guanylyl cyclase α1β1. Biol Chem 394:261–270PubMedCrossRefGoogle Scholar
  11. Beste KY, Spangler CM, Burhenne H, Koch KW, Shen Y, Tang WJ, Kaever V, Seifert R (2013) Nucleotidyl cyclase activity of particulate guanylyl cyclase A: comparison with particulate guanylyl cyclases E and F, soluble guanylyl cyclase and bacterial adenylyl cyclases CyaA and edema factor. PLoS One 8, e70223PubMedPubMedCentralCrossRefGoogle Scholar
  12. Bloch A, Dutschman G, Maue R (1974) Cytidine 3′,5′-monophosphate (cyclic CMP) - II. Initiation of leukemia L-1210 cell growth in vitro. Biochem Biophys Res Commun 59:955–959PubMedCrossRefGoogle Scholar
  13. Borst P, de Wolf C, van de Wetering K (2007) Multidrug resistance-associated proteins 3, 4, and 5. Pflügers Arch 453:661–673PubMedCrossRefGoogle Scholar
  14. Brown EG, Al-Najafi T, Newton RP (1977) Cyclic nucleotide phosphodiesterase activity in Phaseolus vulgaris. Phytochemistry 16:1333–1337CrossRefGoogle Scholar
  15. Brus R, Herman ZS, Juraszczyk Z, Krzemiński T, Trzeciak H, Kurcok A (1984) Central action of cyclic: 3′,5′-thymidine, 3′,5′-uridine and 3′,5′-citidine monophosphates in rat. Acta Med Pol 25:1–9PubMedGoogle Scholar
  16. Butcher RW, Sutherland EW (1962) Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine. J Biol Chem 237:1244–1250PubMedGoogle Scholar
  17. Chen ZS, Lee K, Kruh GD (2001) Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276:33747–33754PubMedCrossRefGoogle Scholar
  18. Chen Z, Zhang X, Ying L, Dou D, Li Y, Bai Y, Liu J, Liu L, Feng H, Yu X, Leung SW, Vanhoutte PM, Gao Y (2014) cIMP synthesized by sGC as a mediator of hypoxic contraction of coronary arteries. Am J Physiol Heart Circ Physiol 307:H328–H336PubMedCrossRefGoogle Scholar
  19. Cheng Y-C, Bloch A (1978) Demonstration, in leukemia L-1210 cells, of a phosphodiesterase acting on 3′:5′-cyclic CMP but not on 3′:5′-cyclic AMP or 3′:5′-cyclic GMP. J Biol Chem 253:2522–2524PubMedGoogle Scholar
  20. Cheung WY (1967) Properties of cyclic 3′,5′-nucleotide phosphodiesterase from rat brain. Biochemistry 4:1079–1087CrossRefGoogle Scholar
  21. Chiatante D, Newton RP, Brown EG (1986) Partial purification and properties of a multifunctional 3′,5′-cyclic nucleotide phosphodiesterase from Lactuca cotyledons. Phytochemistry 25:1545–1551CrossRefGoogle Scholar
  22. Chiatante D, Newton RP, Brown EG (1987) Properties of a multifunctional 3′,5′-cyclic nucleotide phosphodiesterase from Lactuca cotyledons: comparison with mammalian enzymes capable of hydrolyzing pyrimidine cyclic nucleotides. Phytochemistry 26:1301–1306CrossRefGoogle Scholar
  23. Chiatante D, Balconi C, Newton RP, Brown EG (1988) Immunoaffinity purification of cyclic nucleotide phosphodiesterase from Lactuca cotyledons. Phytochemistry 27:2477–2483CrossRefGoogle Scholar
  24. Chiatante D, Newton RP, Crignola S, Levi M, Brown EG (1990) The 3′,5′-cyclic nucleotide phosphodiesterases of meristematic and differentiated tissues of pea roots. Phytochemistry 29:2815–2820CrossRefGoogle Scholar
  25. Conn HO, Karl IS, Steiner A, Kipnis DM (1971) Studies of the mechanism of action of 3′,5′-cyclic nucleotides on hepatic glucose production. Biochem Biophys Res Commun 45:436–443PubMedCrossRefGoogle Scholar
  26. Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti LG, Russel FG, Shayo C, Davio C (2011) Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem 286:6979–6988PubMedPubMedCentralCrossRefGoogle Scholar
  27. Dallas S, Miller DS, Bendayan R (2006) Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev 58:140–161PubMedCrossRefGoogle Scholar
  28. Dittmar F, Abdelilah-Seyfried S, Tschirner SK, Kaever V, Seifert R (2015) Temporal and organ-specific detection of cNMPs including cUMP in the zebrafish. Biochem Biophys Res Commun 468:708–712PubMedCrossRefGoogle Scholar
  29. Drummond GI, Perrott-Yee S (1961) Enzymatic hydrolysis of adenosine 3′,5′-phosphoric acid. J Biol Chem 236:1126–1129PubMedGoogle Scholar
  30. Fischer U, Amrhein N (1974) Cyclic nucleotide phosphodiesterase of Chlamydomonas reinhardtii. Biochim Biophys Acta 341:412–420PubMedCrossRefGoogle Scholar
  31. Francis SH, Blount MA, Corbin JD (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 91:651–690PubMedCrossRefGoogle Scholar
  32. Fredholm BB (2010) Adenosine receptors as drug targets. Exp Cell Res 316:1284–1288PubMedPubMedCentralCrossRefGoogle Scholar
  33. Frizzo ME, Antunes Soares FA, Dall’Onder LP, Lara DR, Swanson RA, Souza DO (2003) Extracellular conversion of guanine-based purines to guanosine specifically enhances astrocyte glutamate uptake. Brain Res 972:84–89PubMedCrossRefGoogle Scholar
  34. Gao Y, Chen Z, Leung SW, Vanhoutte PM (2015) Hypoxic vasospasm mediated by cIMP: when soluble guanylyl cyclase turns bad. J Cardiovasc Pharmacol 65:545–548PubMedPubMedCentralCrossRefGoogle Scholar
  35. Giannattasio M, Sica G, Macchia V (1974) Cyclic AMP phosphodiesterase from dormant tubers of Jerusalem artichoke. Phytochemistry 13:2729–2733Google Scholar
  36. Godinho RO, Duarte T, Pacini ES (2015) New perspectives in signaling mediated by receptors coupled to stimulatory G protein: the emerging significance of cAMP efflux and extracellular cAMP-adenosine pathway. Front Pharmacol 6:58. doi: 10.3389/fphar.2015.00058 PubMedPubMedCentralCrossRefGoogle Scholar
  37. Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, Schultz JE (2006) cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem 281:2841–2846PubMedCrossRefGoogle Scholar
  38. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD (2003) MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J Biol Chem 278:29509–29514PubMedCrossRefGoogle Scholar
  39. Hara Y, Sassi Y, Guibert C, Gambaryan N, Dorfmüller P, Eddahibi S, Lompré AM, Humbert M, Hulot JS (2011) Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest 121:2888–2897PubMedPubMedCentralCrossRefGoogle Scholar
  40. Hardman JG, Sutherland EW (1965) A cyclic 3′,5′-nucleotide phosphodiesterase from heart with specificity for uridine 3′,5′-phosphate. J Biol Chem 240:3704–3705PubMedGoogle Scholar
  41. Hardman JG, Davis JW, Sutherland EW (1966) Measurement of guanosine 3′,5′-monophosphate and other cyclic nucleotides. Variations in urinary excretion with hormonal state of the rat. J Biol Chem 241:4812–4815PubMedGoogle Scholar
  42. Harris DN, Chasin M, Phillips MB, Goldenberg H, Samaniego S, Hess SM (1973) Effect of cyclic nucleotides on activity of cyclic 3′,5′-adenosine monophosphate phosphodiesterase. Biochem Pharmacol 22:221–228PubMedCrossRefGoogle Scholar
  43. Hartwig C, Bähre H, Wolter S, Beckert U, Kaever V, Seifert R (2014) cAMP, cGMP, cCMP and cUMP concentrations across the tree of life: High cCMP and cUMP levels in astrocytes. Neurosci Lett 579:183–187PubMedCrossRefGoogle Scholar
  44. Helfman DM, Kuo JF (1982a) A homogenous cyclic CMP phosphodiesterase hydrolyzes both pyrimidine and purine cyclic 2′:3′- and 3′:5′-nucleotides. J Biol Chem 257:1044–1047PubMedGoogle Scholar
  45. Helfman DM, Kuo JF (1982b) Differential effects of various phosphodiesterase inhibitors, pyrimidine and purine compounds, and inorganic phosphates on cyclic CMP, cyclic AMP and cyclic GMP phosphodiesterases. Biochem Pharmacol 31:43–47PubMedCrossRefGoogle Scholar
  46. Helfman DM, Brackett NL, Kuo JF (1978) Depression of cytidine 3′:5′-cyclic monophosphate phosphodiesterase activity in developing tissues of guinea pigs. Proc Natl Acad Sci USA 75:4422–4425PubMedPubMedCentralCrossRefGoogle Scholar
  47. Helfman DM, Shoji M, Kuo JF (1981) Purification to homogeneity and general properties of a novel phosphodiesterase hydrolyzing cyclic CMP and cyclic cAMP. J Biol Chem 256:6327–6334PubMedGoogle Scholar
  48. Honorat M, Terreux R, Falson P, Di Pietro A, Dumontet C, Payen L (2013) Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2′-deoxyuridine-5′-monophosphate on ABCC11 in silico models. BMC Struct Biol 13:7PubMedPubMedCentralCrossRefGoogle Scholar
  49. Ito M, Tanaka T, Saitoh M, Masuoka H, Nakano T, Hidaka H (1988) Selective inhibition of cyclic AMP phosphodiesterase from various human tissues by milrinone, a potent cardiac bipyridine. Biochem Pharmacol 37:2041–2044PubMedCrossRefGoogle Scholar
  50. Jackson EK, Raghvendra DK (2004) The extracellular cyclic AMP-adenosine pathway in renal physiology. Annu Rev Physiol 66:571–599PubMedCrossRefGoogle Scholar
  51. Jäger R, Schwede F, Genieser HG, Koesling D, Russwurm M (2010) Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5. Br J Pharmacol 161:1645–1660PubMedPubMedCentralCrossRefGoogle Scholar
  52. Jäger R, Russwurm C, Schwede F, Genieser HG, Koesling D, Russwurm M (2012) Activation of PDE10 and PDE11 phosphodiesterases. J Biol Chem 287:1210–1219PubMedCrossRefGoogle Scholar
  53. Jedlitschky G, Burchell B, Keppler D (2000) The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 275:30069–30074PubMedCrossRefGoogle Scholar
  54. Klotz U, Stock K (1971) Evidence for a cyclic nucleotide-phosphodiesterase with high specificity for cyclic uridine-3′,5′-monophosphate in rat adipose tissue. Naunyn Schmiedebergs Arch Pharmacol 269:117–120PubMedCrossRefGoogle Scholar
  55. Krawutschke C, Koesling D, Russwurm M (2015) Cyclic GMP in vascular relaxation: export is of similar importance as degradation. Arterioscler Thromb Vasc Biol 35:2011–2019PubMedCrossRefGoogle Scholar
  56. Kuo JF, Brackett NL, Shoji M, Tse J (1978) Cytidine 3′:5′-monophosphate phosphodiesterase in mammalian tissues. J Biol Chem 253:2518–2521PubMedGoogle Scholar
  57. Lavan BE, Lakey T, Houslay MD (1989) Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form. Biochem Pharmacol 38:4123–4136PubMedCrossRefGoogle Scholar
  58. Laue S, Winterhoff M, Kaever V, van den Heuvel JJ, Russel FG, Seifert R (2014) cCMP is a substrate for MRP5. Naunyn Schmiedebergs Arch Pharmacol 387:893–895PubMedCrossRefGoogle Scholar
  59. Lin PP-C, Varner JE (1972) Cyclic nucleotide phosphodiesterase in pea seedlings. Biochim Biophys Acta 276:454–474PubMedCrossRefGoogle Scholar
  60. Mendel DB, Cihlar T, Moon K, Chen MS (1997) Conversion of 1-[((S)-2-Hydroxy-2-Oxo-1,4,2-Dioxaphosphorinan-5-yl)Methyl]Cytosine to Cidofovir by an Intracellular Cyclic CMP Phosphodiesterase. Antimicrob Agents Chemother 41:641–646PubMedPubMedCentralGoogle Scholar
  61. Michaeli T (2006) PDE 7 (chapter 9). In: Francis SH, Beavo JA, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, pp 195–202Google Scholar
  62. Monzel M, Kuhn M, Bähre H, Seifert R, Schneider EH (2014) PDE7A1 hydrolyzes cCMP. FEBS Lett 588:3469–3474PubMedCrossRefGoogle Scholar
  63. Morrow KA, Seifert R, Kaever V, Britain AL, Sayner SL, Ochoa CD, Cioffi EA, Frank DW, Rich TC, Stevens T (2015) Heterogeneity of pulmonary endothelial cyclic nucleotide response to Pseudomonas aeruginosa ExoY infection. Am J Physiol Lung Cell Mol Physiol 309:L1199–L1207PubMedPubMedCentralGoogle Scholar
  64. Nair KG (1966) Purification and properties of 3′,5′-cyclic nucleotide phosphodiesterase from dog heart. Biochemistry 5:150–157PubMedCrossRefGoogle Scholar
  65. Newton RP, Salih S (1986) Cyclic CMP phosphodiesterase: isolation, specificity and kinetic properties. Int J Biochem 18:743–752PubMedCrossRefGoogle Scholar
  66. Newton RP, Bayliss MA, Khan JA, Bastani A, Wilkins ACR, Games DE, Walton TJ, Brenton AG, Harris FM (1999) Kinetik analysis of cyclic CMP-specific and multifunctional phosphodiesterase by quantitative positive-ion fast-atom bombardment mass spectrometry. Rapid Commun Mass Spectrom 13:574–584PubMedCrossRefGoogle Scholar
  67. Okabayashi T, Ide M (1970) Cyclic 3′,5′-nucleotide phosphodiesterase of Serratia marcescens. Biochim Biophys Acta 220:116–123PubMedCrossRefGoogle Scholar
  68. Okada D, Asakawa S (2002) Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP. Biochemistry 41:9672–9679PubMedCrossRefGoogle Scholar
  69. Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100:309–327PubMedCrossRefGoogle Scholar
  70. Rall TW, Sutherland EW (1958) Formation of a cyclic adenine ribonucleotide by tissue particles. J Biol Chem 232:1065–1076PubMedGoogle Scholar
  71. Reinecke D, Burhenne H, Sandner P, Kaever V, Seifert R (2011) Human cyclic nucleotide phosphodiesterases possess a much broader substrate-specificity than previously described. FEBS Lett 585:3259–3262PubMedCrossRefGoogle Scholar
  72. Reinecke D, Schwede F, Genieser H-G, Seifert R (2013) Analysis of substrate specificity and kinetics of cyclic nucleotide phosphodiesterases with N'-methylanthraniloyl-substituted purine and pyrimidine 3′,5′-cyclic nucleotides by fluorescence spectrometry. PLoS One 8, e54158PubMedPubMedCentralCrossRefGoogle Scholar
  73. Richter W, Conti M (2004) The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. J Biol Chem 279:30338–30348PubMedCrossRefGoogle Scholar
  74. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA (2003) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22:469–478PubMedPubMedCentralCrossRefGoogle Scholar
  75. Sager G (2004) Cyclic GMP transporters. Neurochem Int 45:865–873PubMedCrossRefGoogle Scholar
  76. Sassi Y, Lipskaia L, Vandecasteele G, Nikolaev VO, Hatem SN, Cohen Aubart F, Russel FG, Mougenot N, Vrignaud C, Lechat P, Lompré AM, Hulot JS (2008) Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation. J Clin Invest 118:2747–2757PubMedPubMedCentralCrossRefGoogle Scholar
  77. Sassi Y, Abi-Gerges A, Fauconnier J, Mougenot N, Reiken S, Haghighi K, Kranias EG, Marks AR, Lacampagne A, Engelhardt S, Hatem SN, Lompre AM, Hulot JS (2012) Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes. FASEB J 26:1009–1017PubMedPubMedCentralCrossRefGoogle Scholar
  78. Sassi Y, Ahles A, Truong DJ, Baqi Y, Lee SY, Husse B, Hulot JS, Foinquinos A, Thum T, Müller CE, Dendorfer A, Laggerbauer B, Engelhardt S (2014) Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation. J Clin Invest 124:5385–5397PubMedPubMedCentralCrossRefGoogle Scholar
  79. Saute JA, da Silveira LE, Soares FA, Martini LH, Souza DO, Ganzella M (2006) Amnesic effect of GMP depends on its conversion to guanosine. Neurobiol Learn Mem 85:206–212PubMedCrossRefGoogle Scholar
  80. Scavennec J, Carcassonne Y, Gastaut J-A (1981) Relationship between the levels of cyclic cytidine 3′:5′-monophosphate, cyclic guanosine 3′:5′-monophosphate, and cyclic adenosine 3′:5′-monophophosphate in urines and leukocytes and the type of human leukemias. Cancer Res 41:3222–3227PubMedGoogle Scholar
  81. Seifert R (2015a) Is cIMP a second messenger with functions opposite to those of cGMP? Naunyn Schmiedebergs Arch Pharmacol 387:897–899CrossRefGoogle Scholar
  82. Seifert R (2015b) cCMP and cUMP: emerging second messengers. Trends Biochem Sci 40:8–15PubMedCrossRefGoogle Scholar
  83. Seifert R, Schultz G (1989) Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides. Trends Pharmacol Sci 10:365–369PubMedCrossRefGoogle Scholar
  84. Seifert R, Schneider EH, Bähre H (2015) From canonical to non-canonical cyclic nucleotides as second messengers: pharmacological implications. Pharmacol Ther 148:154–184PubMedCrossRefGoogle Scholar
  85. Shoji M, Brackett NL, Kuo JF (1978a) Cytidine 3′,5′-monophosphate phosphodiesterase: decreased activity in the regenerating and developing liver. Science 201:826–828PubMedCrossRefGoogle Scholar
  86. Shoji M, Brackett NL, Helfman DM, Morris HP, Kuo JF (1978b) Decreased activity of cytidine 3′:5′-monophosphate (cyclic CMP) phosphodiesterase in the fast-growing Morris hepatoma 3924A, but not in the slow-growing Morris hepatoma 9618A. Biochem Biophys Res Commun 83:1140–1146PubMedCrossRefGoogle Scholar
  87. Soares FA, Schmidt AP, Farina M, Frizzo ME, Tavares RG, Portela LV, Lara DR, Souza DO (2004) Anticonvulsant effect of GMP depends on its conversion to guanosine. Brain Res 1005:182–186PubMedCrossRefGoogle Scholar
  88. Stangherlin A, Zoccarato A (2015) Relax: it’s not all about degradation. Arterioscler Thromb Vasc Biol 35:1907–1909PubMedCrossRefGoogle Scholar
  89. Sutherland EW, Rall TW (1960) The relation of adenosine-3′,5′-phosphate and phosphorylase to the actions of catecholamines and other hormones. Pharmacol Rev 12:265–299Google Scholar
  90. Thompson WJ, Appleman MM (1971) Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10:311–316PubMedCrossRefGoogle Scholar
  91. Van Haastert PJ, Van Lookeren Campagne MM (1984) Transient kinetics of a cGMP-dependent cGMP-specific phosphodiesterase from Dictyostelium discoideum. J Cell Biol 98:709–716PubMedCrossRefGoogle Scholar
  92. Wang H, Liu Y, Chen Y, Robinson H, Ke H (2005) Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 280:30949–30955PubMedCrossRefGoogle Scholar
  93. Wei J-W, Hickie RA (1983) Decreased activities of cyclic cytidine 3′,5′-monophosphate phosphodiesterase in Morris hepatomas having varying growth rates. Int J Biochem 15:789–795PubMedCrossRefGoogle Scholar
  94. Wen J, Luo J, Huang W, Tang J, Zhou H, Zhang W (2015) The pharmacological and physiological role of multidrug-resistant protein 4. J Pharmacol Exp Ther 354:358–375PubMedCrossRefGoogle Scholar
  95. Werner K, Kälble S, Wolter S, Schneider EH, Buschauer A, Neumann D, Seifert R (2015) Flow cytometric analysis with a fluorescently labeled formyl peptide receptor ligand as a new method to study the pharmacological profile of the histamine H2 receptor. Naunyn Schmiedebergs Arch Pharmacol 388:1039–1052PubMedCrossRefGoogle Scholar
  96. Wolter S, Kloth C, Golombek M, Dittmar F, Försterling L, Seifert R (2015) cCMP causes caspase-dependent apoptosis in mouse lymphoma cell lines. Biochem Pharmacol 98:119–131PubMedCrossRefGoogle Scholar
  97. Worby A, Mensah LM, Murray KJ (1991) Identification of the novel rat liver IBMX-insensitive phosphodiesterase as a non-specific phosphodiesterase capable of hydrolyzing cCMP. Biochem Pharmacol 42:1318–1321PubMedCrossRefGoogle Scholar
  98. Xu HL, Gavrilyuk V, Wolde HM, Baughman VL, Pelligrino DA (2004a) Regulation of rat pial arteriolar smooth muscle relaxation in vivo through multidrug resistance protein 5-mediated cGMP efflux. Am J Physiol Heart Circ Physiol 286:H2020–H2027PubMedCrossRefGoogle Scholar
  99. Xu HL, Wolde HM, Gavrilyuk V, Baughman VL, Pelligrino DA (2004b) cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo. Am J Physiol Heart Circ Physiol 287:H2501–H2509PubMedCrossRefGoogle Scholar
  100. Yamasaki F, Hayashi H (1982) Comparison of properties of the cellular and extracellular phosphodiesterases induced by cyclic adenosine 3′,5′-monophosphate in Dictyostelium discoideum. J Biochem 91:981–988PubMedCrossRefGoogle Scholar
  101. Yao H, Sem DS (2005) Cofactor fingerprinting with STD NMR to characterize proteins of unknown function: identification of a rare cCMP cofactor preference. FEBS Lett 579:661–666PubMedCrossRefGoogle Scholar
  102. Zan-Kowalczewska M, Bartkiewicz M, Sierakowska H, Shugar D (1984) Purification and resolution of potato tuber cyclic nucleotide phosphodiesterase from nucleotide pyrophosphatase. Biochim Biophys Acta 788:62–73CrossRefGoogle Scholar
  103. Zan-Kowalczewska M, Cieśla J, Sierakowska H, Shugar D (1987) Potato tuber cyclic-nucleotide phosphodiesterase: selective inactivation of activity vs. nucleoside cyclic 3′,5′-phosphates and properties of the native and selectively inactivated enzyme. Biochemistry 26:1194–1200CrossRefGoogle Scholar
  104. Zoraghi R, Bessay EP, Corbin JD, Francis SH (2005) Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280:12051–12063PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2016

Authors and Affiliations

  1. 1.Institute of Pharmacology, Medical School of HannoverHannoverGermany

Personalised recommendations

Cite chapter

Buy options